News stories about Nevro (NYSE:NVRO) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nevro earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 46.9163869261861 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Nevro (NVRO) opened at $70.50 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 8.78 and a quick ratio of 6.81. Nevro has a 1-year low of $65.00 and a 1-year high of $99.63.
Nevro (NYSE:NVRO) last released its earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.02. The firm had revenue of $82.26 million during the quarter, compared to analysts’ expectations of $80.50 million. Nevro had a negative return on equity of 17.27% and a negative net margin of 14.09%. The company’s revenue was up 35.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.14) EPS. sell-side analysts predict that Nevro will post -1.27 earnings per share for the current fiscal year.
A number of research firms have issued reports on NVRO. BMO Capital Markets reiterated a “buy” rating and set a $100.00 target price on shares of Nevro in a report on Thursday. BidaskClub cut Nevro from a “hold” rating to a “sell” rating in a report on Saturday, October 28th. TheStreet upgraded Nevro from a “d+” rating to a “c-” rating in a report on Monday, November 6th. Northland Securities reiterated a “buy” rating and set a $96.00 target price on shares of Nevro in a report on Tuesday, November 7th. Finally, Leerink Swann reiterated an “outperform” rating and set a $110.00 target price (up previously from $105.00) on shares of Nevro in a report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. Nevro currently has a consensus rating of “Hold” and an average target price of $99.25.
In other news, Director Michael F. Demane sold 5,000 shares of the firm’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $93.50, for a total value of $467,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew H. Galligan sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $75.11, for a total value of $525,770.00. The disclosure for this sale can be found here. Insiders sold a total of 17,000 shares of company stock valued at $1,450,770 in the last 90 days. 12.10% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This report was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://ledgergazette.com/2017/12/15/nevro-nvro-getting-somewhat-favorable-press-coverage-accern-reports.html.
Nevro Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.